Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient
Osteoarthritis
About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Total knee arthroplasty, Duloxetine
Eligibility Criteria
Inclusion Criteria:
- Patients for total knee arthroplasty
- having medicare insurance
- CSI(Central sensitization inventory)> 40 (Central sensitization patient )
Exclusion Criteria:
- Rheumatoid arthritis
- Other inflammatory arthritis
- Neuropsychiatric patients
- Allergy or intolerance to study medications
- Patients with an ASA(American society of anesthesiologist) classification of IV (angina, congestive heart failure, dementia, cerebrovascular accident)
- Chronic gabapentin or pregabalin use (regular use for longer than 3 months)
- Chronic opioid use (taking opioids for longer than 3 months)
- Alcohol, drug abuser
- Narcotics addiction
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Duloxetine group
routine pain control group
Experimental: Duloxetine group Phase I (preemptive): 1day before operation (30mg for 1 day) Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone) Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon
Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone